OCD test: OCI-R vs Y-BOCS — which instrument for which task

10 min read

May 17, 2026

For Specialists

Foa E.B. et al. — Psychological Assessment, 2002, N=1,135 (215 OCD + 243 other anxiety + 677 non-anxious)

OCI-R cut-off ≥21

a standard threshold for referral based on self-report screening. The mean OCD clinical score is 28.0 of 72 (SD 13.5). OCI-R takes 5 minutes to complete; sensitivity and specificity at cut-off 21 are adequate, varying by comparison group (Foa 2002). It is a <em>screening instrument</em>: a positive screen means a referral for clinical assessment, not a diagnosis. The gold standard for severity and diagnostic verification is Y-BOCS (clinician-rated, 30–45 minutes, Goodman et al. 1989).

Effectiveness of OCD interventions (Skapinakis 2016 NMA, 54 RCT, N=6,652)

Behavioural therapy (ERP) vs placebo

Y-BOCS −14,5

Cognitive therapy vs placebo

Y-BOCS −13,4

CBT (mixed) vs placebo

Y-BOCS −5,4

Clomipramine vs placebo

Y-BOCS −4,7

SSRI class effect vs placebo

Y-BOCS −3,5

OCD per DSM-5 and ICD-11: what defines the diagnosis

The query "OCD test" attracts roughly 6,569 monthly impressions on the head-term (after filtering out "ОКР мир" — a school subject), and ~7,800 in the broader cluster including "in adults", "in adolescents", "online". The audience is mixed: clinicians look for a validated instrument, clients want a quick screen or confirmation that what they experience has a name.

DSM-5 (APA 2013) defines obsessive-compulsive disorder as the combination of obsessions (recurrent, intrusive, unwanted thoughts, images, or urges) and compulsions (repetitive behaviours or mental acts performed in response to obsessions). Criterion: takes more than 1 hour per day or causes significant distress or impairment. OCD is in its own cluster "Obsessive-Compulsive and Related Disorders" alongside body dysmorphic disorder, hoarding disorder, trichotillomania (hair-pulling), and excoriation (skin-picking). ICD-11 (WHO, in effect from 2022) uses a similar definition in code 6B20 within the "Obsessive-compulsive or related disorders" group.

Ruscio et al. (2010, Molecular Psychiatry, 15(1):53–63) in a representative sub-sample of the National Comorbidity Survey Replication (N=2,073) showed lifetime DSM-IV OCD prevalence of 2.3% and 12-month 1.2%. More than 25% of participants reported lifetime obsessions or compulsions below the diagnostic threshold (subthreshold). This means obsessive patterns occur substantially more often than the diagnosis itself, and part of the "OCD test" audience are people with subthreshold experience who need to distinguish the norm, subclinical, and clinical levels.

Key fact

OCD is a clinical diagnosis with clear DSM-5 / ICD-11 criteria. Self-report screening (OCI-R) helps identify signs and route to assessment, but it is not equivalent to a diagnosis. Final clinical verification is a clinician-administered interview plus Y-BOCS as the gold-standard severity measure. The same principle applies as for depression (see PHQ-9 as screening, not a diagnosis): screening yields probability, the diagnosis is made by a clinician across all available data.

OCI-R: what it measures and what it is for

OCI-R (Obsessive-Compulsive Inventory — Revised) is a revision of Foa's original OCI. Foa, Huppert, Leiberg, Langner, Kichic, Hajcak & Salkovskis (2002, Psychological Assessment, 14(4):485–496) developed and validated the 18-item short form on a sample of N=1,135 (215 OCD patients + 243 patients with other anxiety disorders + 677 non-anxious controls). Structure: 6 subscales of 3 items each — washing, checking, ordering, obsessing, hoarding, neutralizing. 5-point Likert (0 = "not at all", 4 = "extremely"), total 0–72.

Psychometric properties. Cronbach α = 0.81 in the OCD sample and 0.85 in non-anxious controls; subscale alphas 0.81–0.93. Test-retest reliability over 1 month in a student sample (Hajcak, Huppert, Simons & Foa 2004, Behaviour Research and Therapy, 42(1):115–123) — r ≈ 0.82 for the total score, adequate for subscales. Cut-off ≥21 is the standard threshold. Sensitivity and specificity at this cut-off vary by comparison group: comparing OCD with other anxiety disorders yields ~65–66% / 64%; comparing with non-anxious controls is markedly higher. This is normal for a self-report screener — it does not differentiate OCD from adjacent anxiety profiles; the clinician does.

What OCI-R is for: primary screening, self-monitoring, treatment outcome tracking when no clinician is available. Completion takes 5 minutes, public domain, no training required. Not suitable for diagnostic confirmation alone or for severity grading in a clinical trial — Y-BOCS is for that. A peer-reviewed Russian-language validation of OCI-R has not been published as of 2026: community translations exist (psytests, lurialab) but without formal psychometric verification on a Russian-language sample. This is an honest gap that Soveria closes by offering OCI-R on its platform with unified interpretation.

Y-BOCS: what it measures and what it is for

Y-BOCS (Yale-Brown Obsessive Compulsive Scale) is the gold standard for OCD severity measurement. Developed by Goodman, Price, Rasmussen, Mazure, Fleischmann, Hill, Heninger & Charney in two parallel 1989 publications in Archives of General Psychiatry: Part I — development & reliability (46(11):1006–1011), Part II — validity (46(11):1012–1016). 10 items, clinician-administered semi-structured interview, each item 0–4. Total 0–40, with separate subtotals for obsessions (5 items) and compulsions (5 items).

Psychometric properties. Cronbach α ≈ 0.89 (Goodman 1989 Part I). Inter-rater reliability — high, ICC for the total score ≈ 0.98 with standard training; individual-item ICCs range 0.80–0.97. Discriminant validity — weak correlations with depression and anxiety confirm that Y-BOCS measures OCD severity specifically (Goodman 1989 Part II). Sensitive to drug-induced change — confirmed in a placebo-controlled fluvoxamine trial inside Goodman 1989 Part II. Common clinical severity bands (introduced via clinical consensus after Goodman 1989): 0–7 subclinical, 8–15 mild, 16–23 moderate, 24–31 severe, 32–40 extreme. Cut-off for clinical OCD is typically ≥16; for inclusion in treatment trials — more often ≥18.

What Y-BOCS is for: diagnostic confirmation, severity grading, treatment outcome tracking in RCTs and clinical practice. It is the primary outcome measure in most OCD treatment trials over the past 35 years — comparing studies is methodologically impossible without it. 30–45 minutes, requires training to administer. On the Soveria platform Y-BOCS is available in clinician-administered format.

Which instrument when — four scenarios

The core distinction is not "which is better" but "for which task". Four typical scenarios in practice are below.

1. First-line screening / self-check. A client or entry-level clinician wants a quick estimate of OCD probability. Instrument: OCI-R. 5 minutes, self-administered, cut-off ≥21 as a referral signal for clinical assessment. Not used as a standalone diagnosis.
2. Diagnostic clarification. A signal from OCI-R or clinical interview exists; clinician-rated verification and severity grading are needed. Instrument: Y-BOCS. Plus a structured clinical interview (MINI / SCID), plus screening for comorbidities.
3. Treatment outcome tracking. The client is in OCD therapy and progress must be recorded. Option A: Y-BOCS at baseline + every 4–6 weeks (gold standard). Option B: OCI-R monthly as self-monitoring between visits. Combinable — not alternatives.
4. Research / clinical trial. Inclusion criterion is typically Y-BOCS ≥16–18; primary outcome is the change in Y-BOCS total. OCI-R is used as a secondary outcome for patient-reported symptoms.

Soveria · Measurement-Based Care

Start practicing MBC — from your first session

14 days free. Soveria integrates into your practice — no method change required.

Try for free

The core operational rule: OCI-R opens the "door" to clinical assessment, Y-BOCS does the work inside it. Both scales are available in the Soveria catalogue and can be used in this configuration without additional integration.

Comorbidity: OCD is rarely isolated

Pinto, Mancebo, Eisen, Pagano & Rasmussen (2006, Journal of Clinical Psychiatry, 67(5):703–711) in the Brown Longitudinal Obsessive Compulsive Study (N=293 adults with primary DSM-IV OCD, treatment-seeking, intake 2001–2004) showed: 91% have a lifetime history of ≥1 comorbid Axis I disorder. OCD rarely comes alone.

What most often co-occurs — ranking by lifetime rates in Pinto 2006 and comparable cohorts:

Major Depressive Disorder (lifetime ~66–67%) — most frequent comorbid, substantially increases suicidal-ideation risk and reduces functioning. Screen with PHQ-9 / BDI-II as a mandatory part of assessment
Anxiety disorders (lifetime ~50–75%) — especially social anxiety, GAD, specific phobias. Screen with GAD-7 for generalised, specific instruments for the rest
Bipolar / hypomanic episodes (lifetime ~10–15%) — critical for medication choice: SSRI without a mood stabiliser can precipitate hypomania in undiagnosed bipolar patients
Obsessive-compulsive personality disorder (~25%) — clinically distinct from OCD but overlaps in presentation. OCPD = perfectionism + rigidity without ego-dystonic obsessions

Practical implication: an OCD assessment includes screening for depression, anxiety, and mood stabiliser indication as a mandatory part, not an option. A long delay between first OCD symptoms and treatment initiation — typically more than a decade in epidemiological data (Pinto et al. 2006; Hollander et al. 1996–1997) — means that by the time of presentation, most clients have accumulated a comorbid profile requiring mapped intervention.

What works empirically in treatment

Skapinakis et al. (2016, Lancet Psychiatry, 3(8):730–739) performed a systematic review and network meta-analysis — 54 RCTs, N=6,652 — and published the most comprehensive comparison of OCD interventions to date. Effect on Y-BOCS vs placebo (mean difference):

Behavioural therapy (ERP, Exposure and Response Prevention) — Y-BOCS −14.5 (95% CrI −18.6 to −10.2). The largest effect in the NMA, monotherapy. Foa, Liebowitz, Kozak et al. (2005, Am J Psychiatry, 162(1):151–161) in a multicentre RCT (N=122): response rate 62% intent-to-treat / 86% completers for EX/RP vs 8% / 10% placebo
Cognitive therapy — Y-BOCS −13.4. Comparable to behavioural in effect
CBT (mixed cognitive + behavioural) — Y-BOCS −5.4. Markedly smaller than pure behavioural therapy, likely due to protocol heterogeneity in this bucket
SSRI class effect — Y-BOCS −3.5 (95% CrI −5.1 to −1.8). Significantly better than placebo, but substantially smaller than psychotherapy. Pittenger & Bloch (2014, Psychiatric Clinics of North America, 37(3):375–391): SSRI is the mainstay of pharmacotherapy, usually at higher doses and longer durations than for depression. Clomipramine as second-line tricyclic

The main meta-analysis conclusion: ERP is first-line in efficacy; SSRI is first-line in accessibility / scalability. In severe OCD, the combination of psychotherapy + medication usually outperforms either monotherapy. This is consistent with the APA OCD Practice Guideline (Koran et al. 2007) and later BAP recommendations. For tracking dynamics in therapy — Y-BOCS at baseline, at 6 weeks, and at 12 weeks; a reliable change on Y-BOCS is typically ≥5-point improvement as the threshold for clinically meaningful response.

When a clinician is needed, and suicide risk

Suicide risk in OCD is clinically higher than many assume. Fernández de la Cruz, Rydell, Runeson, D'Onofrio, Brander, Rück, Lichtenstein, Larsson & Mataix-Cols (2017, Molecular Psychiatry, 22(11):1626–1632) in a population-based study using Swedish national registers — 36,788 OCD patients matched 1:10 to population controls. Unadjusted OR for death by suicide is 9.83 (95% CI 8.72–11.08) — nearly 10× the population rate. OR for attempted suicide is 5.45 (95% CI 5.24–5.67). After adjusting for psychiatric comorbidities, risk decreases but remains substantial — that is, OCD is an independent risk factor, not only via comorbid depression. The strongest predictor of death is a previous suicide attempt.

Specific escalation criteria:

OCI-R ≥ 21 or Y-BOCS ≥ 16 → clinician mandatory. ERP-trained CBT therapist plus SSRI consideration
OCI-R 12–20 or Y-BOCS 8–15 → consider a clinician, especially if there is functional impairment or distress
Any active suicidal thoughts with plan or intent → immediate contact, crisis line or emergency department. Self-help is inappropriate in this case (see decision tree)
Comorbid bipolar features (elevated-mood episodes, decreased need for sleep) → psychiatrist before starting an SSRI, not a GP — without a mood stabiliser, SSRI can precipitate hypomania

Practical takeaway

OCD is a serious disorder with a ~10× elevated suicide risk (Fernández de la Cruz 2017) but treatable. ERP + SSRI is the established gold standard; ERP response rate in the Foa 2005 RCT is 62–86% (vs 8–10% placebo). OCI-R provides quick screening (5 minutes), Y-BOCS provides clinical depth (30–45 minutes). Both are available in the Soveria catalogue. The key principle: do not use self-report as a substitute for clinical evaluation — OCD almost always requires a clinician, especially at OCI-R ≥21 or Y-BOCS ≥16, and almost always has comorbidities that also need screening (PHQ-9, GAD-7 at minimum).

Sources / Источники
Foa E.B., Huppert J.D., Leiberg S., Langner R., Kichic R., Hajcak G., Salkovskis P.M. (2002). The Obsessive-Compulsive Inventory: development and validation of a short version. Psychological Assessment, 14(4), 485–496. · Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., Charney D.S. (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry, 46(11), 1006–1011. · Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., Charney D.S. (1989). The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry, 46(11), 1012–1016. · Hajcak G., Huppert J.D., Simons R.F., Foa E.B. (2004). Psychometric properties of the OCI-R in a college sample. Behaviour Research and Therapy, 42(1), 115–123. · Ruscio A.M., Stein D.J., Chiu W.T., Kessler R.C. (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 15(1), 53–63. · Pinto A., Mancebo M.C., Eisen J.L., Pagano M.E., Rasmussen S.A. (2006). The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry, 67(5), 703–711. · Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., Huppert J.D., Kjernisted K., Rowan V., Schmidt A.B., Simpson H.B., Tu X. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry, 162(1), 151–161. · Skapinakis P., Caldwell D.M., Hollingworth W., Bryden P., Fineberg N.A., Salkovskis P., Welton N.J., Baxter H., Kessler D., Churchill R., Lewis G. (2016). Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry, 3(8), 730–739. · Fernández de la Cruz L., Rydell M., Runeson B., D'Onofrio B.M., Brander G., Rück C., Lichtenstein P., Larsson H., Mataix-Cols D. (2017). Suicide in obsessive-compulsive disorder: a population-based study of 36 788 Swedish patients. Molecular Psychiatry, 22(11), 1626–1632. · Pittenger C., Bloch M.H. (2014). Pharmacological treatment of obsessive-compulsive disorder. Psychiatric Clinics of North America, 37(3), 375–391. · American Psychiatric Association (2013). DSM-5. · World Health Organization (2022). ICD-11.